The primary end point was a plasma HIV type 1 RNA level of at least 50 copies per milliliter at week 48, assessed on the basis of the Food and Drug Administration snapshot algorithm.
The Expert Committee is responsible for updating the WHO Model List of Essential Medicines
Collaborative Efforts Aim to Curb Antimicrobial Resistance and Enhance Antibiotic Prescription Practices
According to researchers, AMR could kill up to 10 million people by the year 2050. A 2019 Lancet report estimated global deaths associated with bacterial AMR of close to 5 million people.
Leading the development of case management guidelines and mentorship of health care workers on case management
Improving identification, management and control of Candida auris in a Kenyan Hospital.
Supporting the development of policies and strategies for surveillance of antibiotic use and consumption.
Working with the National AIDS and STI Control program (NASCOP) to improve HIV care in Kenya and develop evidence based guidelines on antiretroviral therapy.
Improving generation, extraction, visualisation and use of clinical data to improve care and resource allocation
Training on data analysis, data wrangling and opportunities to engage in epidemiological and clinical research.
FUNDED RESEARCH
-
Ombajo L.A with Thumbi Mwangi Nov 2022 - Nov 2027. (Funding: Bill and Melinda Gates Foundation.) Incubation grant for Center for Epidemiological Modelling and Analysis.
-
Ombajo L.A Oct 2022- Oct 2025. Sub-award from London School of Hygiene and Tropical Medicine for a collaborative randomised clinical trial.
Improving HIV 1 Control in Africa with Long Acting Injectables (IMPALA) clinical trial -
Ombajo L.A Aug 2022-March 2023. (Funding: Fleming Country Grant Fund).
Improving Antimicrobial Resistance(AMR) surveillance in Kenya -
Ombajo L.A Sept 2021- September 2026. Award number 1 NU3HCK000004-01-00, (Funding: Center for Disease Control and Prevention(CDC))
Monitor and Prevent Antimicrobial Resistance in Kenya (MAP-AMR Kenya) -
Ombajo L.A (PI, collaboration with Drs Thumbi Mwangi-UoN and Shikoh Gitau-Qhala limited) 05/2020 – 05/2022 (Funding: Bill and Melinda Gates Foundation)
Project title: Kenya Data for Health: optimizing COVID-19 responses through data.
Summary: This project is focused on infectious disease modelling for COVID-19 in Kenya to inform government responses to the disease in Kenya, data analysis and monitoring of non-COVID-19 health metrics to understand and estimate the impact of COVID-19 pandemic on health, and the analysis and visualization of health data to aid in decision making in Kenya.
-
Ombajo L.A ( PI, collaboration with Drs. Jeremy Penner and Jared Mecha - UoN) 18/2020-08/2022 (Investigator Sponsored study with funding from Gilead Sciences)
Project title: B/F/TAF elderly study: Switching virally suppressed HIV-1 infected elderly adults (age≥60 years) without prior confirmed virological failure from current ARV regimen to B/F/TAF: An Open-Label Randomised Controlled Trial.
-
Ombajo L.A Young Investigator Award - Biomerieux/KAVI-ICR for research on Animicrobial resistance.
Summary: This award supports on-going work on antimicrobial resistance in Kenya with a focus on improving understanding of Candida auris prevention in critical care units.
-
Ombajo L.A (Co-PI, collaboration with Dr. Amanj Kurdi - Strathclyde University) Sept 2019-Sept 2020 (SFC Global Challenges Research Fund Institutional Sponsorship Award – University of Strathclyde)
Project title: GAPS IN IDENTIFICATION AND MANAGEMENT OF CARDIOVASCULAR DISEASE IN HIV PATIENTS AT 5 HIV CLINICS IN KENYA.
-
Ombajo L.A (PI UoN, collaborations with PATH international as prime grant recipient, KEMRI, AgaKhan University, ILRI) 09/2019-02/2022 (Funding UKAID through Fleming Fund) Project title: Improving Antimicrobial Resistance(AMR) surveillance in Kenya
Summary: Supporting surveillance of antibiotic resistance, antibiotic use and consumption in various Kenyan Hospitals, supporting establishment of antimicrobial stewardship and development of antibiotic use guidelines.
-
Ombajo L.A (PI, collaboration with Drs. Jeremy Penner, Jared Mecha, Anton Pozniak) 09/2019-01/2021 (Investigator sponsored study with funding from ViiV Healthcare)
Project title: 2SD -Switching Treatment-Experienced, Integrase Inhibitor-Naïve, Virally Suppressed HIV 1 Infected Adults from PI/r to DTG: An Open-Label Randomized Controlled Trial.
-
Ombajo L.A (Co-I, collaboration with Prof Marion Bernie, Margaret Oluka, Amanj Kurdi,Anastasia Guantai, Brian Godman, Sylvia Opanga) 05/2017-2019 (Funding - Newton Fund)
Project title: Sustainable health interventions to tackle the emerging threat of antimicrobial resistance and the rapid rise in non-communicable diseases: a road map to improved public health in Kenya
